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Background: Geranium wilfordii is one of the major species used as Herba Geranii (lao-guan-cao) in China, it is
commonly used solely or in polyherbal formulations for treatment of joint pain resulted from rheumatoid arthritis
(RA) and gout. This herb is used to validate a target-based drug screening platform called Herbochip® and evaluate
anti-inflammatory effects of Geranium wilfordii ethanolic extract (GWE) using tumor necrosis factor-alpha (TNF-α) as
a drug target together with subsequent in vitro and in vivo assays.
Methods: A microarray-based drug screening platform was constructed by arraying HPLC fractions of herbal
extracts onto a surface-activated polystyrene slide (Herbochip®). Using TNF-α as a molecular probe, fractions of
82 selected herbal extracts, including GWE, were then screened to identify plant extracts containing TNF-α-binding
agents. Cytotoxicity of GWE and modulatory effects of GWE on TNF-α expression were evaluated by cell-based
assays using TNF-α sensitive murine fibrosarcoma L929 cells as an in vitro model.
Results: The in vivo anti-inflammatory effects of GWE were further assessed by animal models including
carrageenan-induced hind paw edema in rats and xylene-induced ear edema in mice, in comparison with aspirin.
The hybridization data obtained by Herbochip® analysis showed unambiguous signals which confirmed TNF-α
binding activity in 46 herbal extracts including GWE. In L929 cells GWE showed significant inhibitory effect
on TNF-α expression with negligible cytotoxicity. GWE also significantly inhibited formation of carrageenan-induced hind
paw edema and xylene-induced ear edema in animal models, indicating that it indeed possessed anti-inflammatory
activity.
Conclusion: We have thus validated effectiveness of the Herbochip® drug screening platform using TNF-α
as a molecular target. Subsequent experiments on GWE lead us to conclude that the anti-RA activity of GWE
can be attributed to inhibitory effect of GWE on the key inflammatory factor, TNF-α. Our results contribute
towards validation of the traditional use of GWE in the treatment of RA and other inflammatory joint disorders.
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The dried aerial parts of Geranium wilfordii Maxim
(GW), Erodium stephanianum Willd., and other congenic
plants including G. Carolinianum in the Geraniaceae
family are used as Chinese medicinal plant lao-guan-cao or
Herba geranii/Herba erodii. According to Pharmacopoeia
of People’s Republic of China 2010 [1], GW is acrid, bitter,
neutral; and liver, kidney, spleen meridian entered.
GW is effective for eliminating wind-dampness, unblock
meridians, as well as stopping diarrhea and dysentery, thus
it is clinically used for treatments of rheumatoid arthritis
(RA), spasm numbness, myalgia, etc., ailments that related
to inflammation, swelling, pain, and other discomforts in
muscles, bones, and joints. GW can be used in polyherbal
formulation such as in Yunnan Baiyao or alone such as in
the lao-guan-cao paste/cream (Unguentum Geranii)
for topical therapy of the aforementioned ailments,
particularly RA [1]. More recent pharmacological
studies indicate that this herb, together with its congenic
plants, also possesses anti-oxidative, anti-viral, anti-cancer,
antinociceptive and others effect [2,3]. Unfortunately,
despite of its wide application in traditional Chinese
medicine, the molecular mechanism underlying its efficacy
has seldom been reported.
RA is a progressive joint damaging and disabling
disease characterized by pain, swelling, and stiffness of the
synovial joints. This autoimmune disease is resulted from
dysregulations of both innate and adaptative immunity, i.e.,
interactions between genetic and environmental factors are
involved [4-6]. Cumulating evidences indicate that RA is
also a chronic inflammatory disease involving many
cytokines that act both in series and in parallel, a
phenomenon known as cytokine network redundancy
[4]. Among the cytokines involved tumor necrosis
factor-alpha (TNF-α) plays a pivotal role in the patho-
genesis and treatments of RA [7,8]. TNF-α inhibitory bio-
logics disease-modifying anti-rheumatic drugs (DMARDs)
such as infliximab, etanercept, adalimumab, certolizumab
and golimumab produced significant therapeutic effects in
large numbers of RA patients [7]. The successful clinical
applications of these TNF-α inhibitors firmly demonstrate
the fact that TNF-α is indeed the key inflammatory
mediator in RA. Unfortunately, these immune-modulators
will cause adverse effects including infusion reactions, injec-
tion site reactions and immunogenicity, as well as increased
risks in malignance, cardiovascular, liver and other auto-
immune diseases [9]. Before the use of these DMARDs,
more conventional drugs used for the management of RA
are steriods and non-steroidal anti-inflammatory drugs
(NSAIDs); but their long-term use is well known to be
associated with serious adverse effects as well. Thus, RA
patients often seek alternative ways and means for
symptomatic relief and are amongst the highest users of
complementary and alternative medicines (CAMs) [10,11].A decade ago, a WHO [12] report stated that more
than 80% of the world market relies on herbal medicinal
products. In fact, use of herbal medicines is an ancient
practice in almost all cultures. In recent years use of
herbal products either as dietary supplements, medical
foods, or therapeutics, has become a common trend
around the world or functional effects have been and
continue to be rigorously studied [13]. Unfortunately,
very few biological targets have been unanimously
identified for the vast amounts of natural products
studied. The most well-known drug target for a number
of natural products may be α-tubulin in microtubules.
Tubulin-binding phytochemicals such as vincristine,
vinblastine, paclitaxel, and ixabepilone are developed to be
frontline anti-cancer drugs [14]. Another highly publicized
example is the identification of SERCA of Plasmodium
falciparum as the drug target of artemisinins (qinghaosu)
[15] from the antimalarial herb Artemisia annua L.
(qinghao) [16,17]. It is worth to note that all of the
target identifications, if any, for herbal compounds are
likely resulted after functional identification and screening.
In 2003, Chang et al. published a microarray-based drug
screening technology (Herbochip®) which allowed func-
tional characterization of herbal compounds fractionated
by HPLC using a defined protein drug target in a reverse
screening fashion. The prototype of this technology was
reported to be used for finding anti-TNF-α active
herbal fractions as mentioned in a patent application
[17]. Subsequently, herbochips containing HPLC fractions
from Sophora flavescens (SFE-herbochip) were screened
using cytochrome P450 3A4 (CYP450 3A4) as a molecular
target, hoping to obtain anti-CYP450 3A4 active compo-
nents that might be useful in the design of regimens for
the treatment of human immunodeficiency virus (HIV)
infection [18]. Herein, we present a refined version of the
Herbochip® platform and report successful identification
of the binding activity toward TNF-α in 46 out of 82
selected herbal extracts. Furthermore, the anti-TNF-α and
anti-inflammatory effects of the GWE were respectively
attested by in vitro and in vivo assays. Our results present
a platform that can be used for drug screening with
known drug targets and contribute towards validation of
the traditional use of GWE in the treatment of RA and
other inflammatory joint disorders.
Methods
Cell line, chemicals and biochemicals
L929 (NCTC clone 929, derivative of Strain L) cells line
was purchased from the China Center for Type Culture
Collection (CCTCC, number: GDC034). Aspirin was from
Shandong Xinhua Pharmaceutical Co. Ltd., Shangdong,
China. Actinomycin D (ActD) was from Beyotime Institute
of Biotechnology, Jiangsu, China. Sodium hydrogen
carbonate, dimethyl sulfoxide, Tween 20, sodium chloride,
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Ltd., Shanghai, China. Other reagents and chemicals were
from Sigma-Aldrich, USA.
Plants and plant extracts
For primary screenings, most of the plant materials of
82 selected Chinese herbs were either self-collected or
purchased from market (Table 1). Specifically, the plant
materials of Geranium wilfordii Maxim were obtained
from Yannan Baiyao Group Tianzihong Pharmaceutical
Co. Ltd. (Kunming, Yunnan, China) and identified by
Yunnan Institute of Materia Medica (Kunming, Yunnan,
China) according to The Pharmacopoeia Commission of
PR China 2010 [1]. Voucher specimens of the whole
plant of G. wilfordii as well as all plant materials
screened were stored in our laboratory (Table 1). Plant
extracts for herbochip screening were prepared as
follows. For each preparation 50 g dried plant materials
was ground to powder and extracted with 1 L 50% ethanol
(1:20 w/v) at room temperature for three days. The extract
was concentrated to 2.5% of its original volume by
vacuum evaporation (R200, Buchi, Swiss Confederation)
at approximately 60°C and then dried by lyophilization
(LGJ-10D, Four-Ring Science Instrument Plant Beijing
Co., Ltd., China). The dry powder was kept at 4°C until
use. Since large amount of ethanolic extract of G. wilfordii
(GWE) was needed in subsequent experiments, the starting
material was increased to 3 kg for preparation of GWE
according to the same protocol. The positive control,
aspirin (95% pure), was obtained from the Shandong
Xinhua Pharmaceutical Co., Ltd. (Zibo, Shandong, China).
Preparation of the herbochips and screening for TNF-α
binding activity
Fractionation of the plant extract by HPLC: The plant
extracts obtained above, including that made from
Geranium wilfordii (GWE), were dissolved in 50%
ethanol to a concentration of 50 mg/mL. The sample
was then resolved into 96 fractions by a HPLC system
equipped with a C18 column, an Agilent1100 instrument,
a quaternary pump, a manual injector, a UV detector and
a workstation for peak identification and integration
(Agilent Technologies, USA). The column used was a
Hypersil ODS C-18 analytical column (4.6 × 250 mm,
5 μm) and the detection wavelength was set at
254 nm. For each fractionation, 50 μL sample was
loaded and the elution was carried out by a water to
EtOH gradient at a constant flow rate of 0.75 mL/min at
30°C for 96 min as follows: 0-50% EtOH (90 min), 50-100%
EtOH (6 min). One-minute fractions were collected and
then 150 μL each fraction was transferred into a 96-well
microplate (Corning Incorporated, USA). Thus each plate
represented a complete HPLC run of the fractions/samples
load. The plates were vacuum-dried by a Speed Vac(Savant, Thermo Fisher Scientific, Germany) and stored at
4°C until use.
Fabrication of herbochips - arraying the HPLC fractions
on plastic slides: The blank chips were manufactured by
mode injection followed by surface-activation [17]. Briefly,
the molded plastic slides (25 mm × 75 mm × 1.4 mm)
with two caves (Figure 1) were made of polystyrene
and surface-activated by consecutive treatments with
glutaraldehyde (0.4%, pH 5.0; room temperature, 4 h;
washed in H2O), NH4OH (3 M, pH 11.0; 60°C, 4 h), and
1,4-butanediol diglycidyl ether (100 mM, pH 11.0; 37°C,
overnight). After treatments, the slides were washed with
0.1 M NaHCO3 (pH 8.0), dried, sealed and stored at 4°C
until use (blank chips). Prior to spotting, 30 μL OptiFix I
(40 mM sodium borate, 0.1 M PBS, 0.01% Tween 20, 20%
DMSO, pH 10.0) was added to each well of the 96-well
plates. The samples were then spotted onto the blank
chips using an automatic arrayer (Biodot A101, Shuai Ran
Precision, Taiwan) according to the format shown in
Figure 1. For controls, biotinamidocaproyl hydrazide
(Sigma, USA) was serially diluted to 4, 10, 50, 250 ng/mL
with OptiFix I (Figure 1, C1 to C4), OptiFix I alone
(Figure 1, C5), 1 μg/mL Cy5-labeled streptavidin (SA-Cy5,
GE Health) in OptiFix II (50 mM sodium tetraborate,
0.1 M PBS, 0.01% Tween 20, pH7.4) were also processed
alongside with the above samples (Figure 1, C6). The
slides were then air-dried and stored at 4°C over-
night. After being blocked with blocking buffer
(0.1 M ethanolamine, 0.1 M sodium tetraborate) for
1 h, they were washed four times with TBST (50 mM
Tris · HCl, 0.15 M NaCl, 0.05% Tween 20, pH 7.5), rinsed
with double distilled water four times, dried at 30 min and
stored at 4°C until used. The resulted slides, with HPLC
fractions arrayed, were designated as herbochips and
named with the herbs used. For instance, GWE-herbochip
is a herbochip that was arrayed with GWE.
Screening TNF-α binding activities in the plant extracts
by using the Herbochip® platform: Purified TNF-α was
purchased from PrimeGene Technical (Shanghai, China).
For preparation of biotinylated TNF-α, 1 mg protein was
dissolved in 1 mL coupling buffer (100 mM NaHCO3,
pH 8.0), and 50 μL the BNHS solution (2 mg/mL biotina-
midohexanoic acid N-hydroxysuccinimide ester in DMSO)
was added. The biotinylation reaction was carried out for
1 h on ice and then stopped by adding equal volume of
glycine (50 mM in coupling buffer). The mixture was then
dialyzed against coupling buffer to remove unreacted
BNHS and excess glycine. For hybridization, each cave on
the chips was covered by a cover glass (22 × 22 mm)
under which 20 μL biotinylated-TNF-α in TBST (50 mM
Tris–HCl, pH 7.5; 0.15 M NaCl, 0.05% Tween 20) or
TBST alone was added. The slides were then incubated at
37°C for 1 h. While placed in a slide washing jar, the
slides were washed in TBST (4 × 2 min), rinsed in water
Table 1 Hybridization reactivity of herbal extracts using TNF-α as a probe on herbochips
Herbal extracts Parts used Specimen number Hybridization reactivity*
Acacia spinosa stem B0210A0402 -
Acer garrettii root A1108A0304 +++
Achyranthes bidentata root A0604A0082 -
Aconitum carmichaeli root A1104A0095 -
Aconitum kusnezoffii root A1203A0096 -
Allemanda blanchetii leaf C1108A0303 -
Amomum kravanh pericarp M0704A0085 +
Angelica pubescens root A0704A0083 -
Angelica sinensis root A0904A0080 -
Atractylodes chinensis stem and root A0604A0084 -
Atractylodes macrocephala stem and root A0804A0081 -
Blinkworthia lycioides stem and leaf H1009B0202 +
Cachlosbermum regium flower D0710C0629 ++
Callisia fragrans leaf C1009C0574 -
Campylotropis yunnanensis stem and leaf H1209C0591 +++
Centrolobium ochroxylum leaf C1009C0578 +++
Chaenomeles speciosa fruit E0904C0131 ++
Chaetocarpus castanocarpus var. pubescens fruit E0710C0634 -
Cinchona succirubra stem B0710C0637 -
Cinnamomum burmannii stem B0210C0621 +++
Cinnamomum cassia stem B0904C0130 ++
Citrus reticulata pericarp M0404C0132 ++
Clematis chinesis root A1104C0144 -
Clinacanthus nutans stem and leaf H1009C0569 -
Cochlospermum vitifolium stem B0210C0624 +++
Codiaeum variegatum cv. Sunny Star leaf C1209C0601 -
Colubrina arborescens stem B0210C0617 +
Curcumorpha longifolia whole plant G1108C0451 -
Cyrtomium fortunei stem and root A1003C0140 ++
Derris tonkinensis stem B1009D0207 +/−
Diospyros xishuangbannaensis stem B0710D0237 +++
Dipsacus asperoides root A0604D0048 -
Eucommia ulmoides bark J0604E0035 +
Garcia nutans stem B0609G0123 +
Ephedra sinica stem B0604E0036 ++
Garcinia bancans leaf C1009G0153 +++
Gardenia erythroslada stem B0609G0125 +
Gastrodia elata root A1104G0038 -
Gentiana crassicaulis root A1004G0037 -
Geranium wilfordii whole plant G0204E0037 ++
Gnetum gnemon var. tenerum fruit E1108G0099 +/−
Harpullia arborea stem B0210H0165 -
Hibiscus rosa-chinensis stem B1009H0157 -
Homalomena occulta stem and root A0604H0034 ++
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Illicium difengpi velamen L1103I0012 +++
Ixora duffii cv. Super King stem B1009I0065 +++
Lantana camara var. flava Moldenke stem and leaf H1108L0127 -
Leea hispida stem B1009L0163 +++
Litsea lancifolia leaf C1108L0138 +++
Lysimachia garrettii whole plant G0609L0142 ++
Millettia chenkangensis fruit E1209M0293 +
Millettia pulchra bark J1108M0229 +
Mussaenda flava stem and leaf H1009M0281 +++
Paris polyphylla Smith var. yunnanensis root A0610P0053 -
Phellodendron amurense bark J0704P0079 -
Pittosporum formosanum hayata var. hainanensis gagnep stem B0210P0403 +
Pogostemon cablin underground G0304P0078 +/−
Polygonum multiflorum root A0304P0089 ++
Poria cocos sporocarp G0904P0084 -
Pueraria thomsonii root A0904P0080 -
Pygeum latifolium stem B0710P0411 +++
Randia wallichii stem B1209R0125 +
Rehmannia glutinosa root A1104R0026 -
Rheum palmatum root A0804R0023 +++
Rivina humilis var. fructu stem/leaf H1108R0087 +/−
Saraca thaipingensis stem B0210S0338 +++
Schefflera menglaensis stem B0210S0326 +
Seseli mairei root A0604S0069 -
Shirakiopsis indica fruit E0210S0337 -
Sinomenium acutum stem B1103S0064 +
Syzygium caryophyllaceum stem B1009S0300 ++
Taraxacum officnala whole plant G1208T0157 -
Taxillus chinensis stem B0904T0042 +++
Ternstroemia gymnanthera var. wightii bark J0308T0129 +++
Tricalysia mollissima root A1108T0155 ++
Typhonium giganteum root stem B1003T0043 -
Uvaria cordata stem B1009U0033 +++
Ventilago madraspatana stem B1108V0050 +++
Vitex glabrata fruit B1108V0047 +/−
Vitex glabrata stem E0210V0059 ++
Vitis balanseana root A0409V0053 +++
Wrightia fruticosa stem B0210W0045 -
* “-” = negative; “+/-” = inconsistent results; “+” = weak positive, Fluorescence Value (FV) < 200; “++” = moderate positive, FV between 200 and 1000;
“+++” = strong positive, FV >1000.
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room temperature, and then dried at 37°C (30 min). The
same hybridization procedure was used in the subsequent
reaction with Cy5-labeled streptavidin (SA-Cy5) where
20 μL 2.5 μg/mL SA-Cy5 in TBST was used. The driedslides were scanned by a laser scanner (GenePix4100 A,
Axon, USA) and the fluorescent intensity of red spots in
the image was analyzed at emission wavelength of 635 nm
by GenePix 5.0 Software. The fluorescence value (FV) of
each hybridization reaction was then recorded.
Figure 1 Schematic illustration of a herbochip. In each of the plastic
slides (25 mm x 75 mm x 1.4 mm), two caves (1 and 2) were molded
and used for control and tested samples. HPLC fractions were spotted
into each cave in duplicates. The 96 fractions from HPLC were formatted
as spots 1 – 96 and there were six control spots (C1 – C6) as illustrated.
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activity of GWE
The TNF-α sensitive murine fibrosarcoma L929 cells
were used for determination of cytotoxicity and inhibitory
effect on TNF-α of the samples. L929 cells were cultured in
RPMI-1640 medium (Gibco, Grand Island, NY, USA) sup-
plemented with 10% fetal bovine serum (FBS), 100 μg/mL
streptomycin, 100 U/mL penicillin, and 0.03% L-glutamine,
and maintained at 37°C in humidified air containing
5% CO2. All the experiments were performed on
logarithmically growing cells. For treatments, the
L929 cells were seeded into 96-well microtiter plates
at a concentration of 1.5 × 104 cells/well in 100 μL of
culture media and allowed to recover for 24 h. The
cells were pretreated with ActD at 2 μg/mL for 1 h
and then with four twofold serial dilutions of the test drug
(GWE dissolved in culture media) for an additional 24,
48, and 72 h. Cell viability was determined by incubation
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) (0.5 mg/mL) for 1 h, solubilization in
dimethyl sulfoxide (DMSO), and spectrophotometricmeasurement at 550 nm [19]. The cytotoxicites of the test
drugs were expressed as % Cell Viability = O.D.ActD+test
drugs/O.D.ActD. Effect of the GWE on TNF-α activity
was evaluated using L929 cell bioassay in the pres-
ence of 1 μg/mL Actinomycin D (ActD) as described
by Kiemer et al. [20]. In brief, L929 cells were seeded
at a density of 1.5 × 104 cells/well in 100 μL of culture
media. Following incubation for 24 h, the medium in the
wells was replaced with fresh medium containing ActD
(2 μg/mL). After 1 h of preincubation with ActD,
serial dilutions of test drugs and a final concentration
of 0.2 ng/mL TNF-α was added. The plates were then
incubated for an additional 24 h at 37°C and then
MTT test was performed as described above. The
TNF-α inhibitory effects of the test drugs were
expressed as % inhibition = (O.D.ActD+TNF-α+test drugs –
O.D.ActD+TNF-α)/(O.D.ActD – O.D.ActD+TNF-α).
In vivo anti-inflammatory activity of GWE
Anti-inflammatory activities of GWE were tested using
rat carrageenan-induced hind paw edema and mouse
xylene-induced ear edema experimental models. The
animal experiments were carried out at Yunnan Institute
of Materia Medica (YIMM) and approved by the Animal
Experimental Ethics Committee of YIMM (Approval
Number: SCXK (Yunnan) 2005–0008). Based on the
recommended dose of the raw drug for human (9 g/d,
China Pharmacopoeia Committee, 2010) [1], the drug dose
used for the animals was calculated to be 6.75 g/kg/d. The
animals were kept in controlled environments and
maintained on standard pellet diet and water ad libitum.
Carrageenan-induced rat hind paw edema model: Male
Sprague–Dawley (SD) rats, weighting 160–210 g, were
used. For each experiment, 30 SD rats were randomized
into 3 groups, untreated control (water), treatments
with GWE (1.69 g/kg/d) and reference drug control
aspirin (0.1 mg/kg/d). Test drugs were administrated
intragastrically each day for 5 consecutive days. One
hour after the last drug dosing, each rat was injected with
0.1 mL freshly prepared suspension of 1% carrageenan in
physiological saline into subplantar tissue of the right hind
paw. Paw edema was then measured at 1, 2, 4, and 6 h
after induction of inflammation.
Xylene-induced mouse ear edema model: Male ICR
mice weighting 18–20 g were used. For each experiment,
30 ICR mice were randomized into 3 groups, untreated
control (water), treatments with GWE (1.69 g/kg/d)
and reference drug control aspirin (0.1 mg/kg/d). Test
drugs were administrated intragastrically each day for
5 consecutive days. One hour after the last drug dosing,
50 μL xylene was applied to both anterior and posterior
surfaces of the right ear for another hour. Subsequently,
discs of 8 mm diameter were removed from each ear and
weighed in a balance. The swelling was estimated as the
Figure 2 Binding signals of representative herbochips probed by β-TNF-α. The images were visualized by Cy5-labeled streptavidin after the
binding of β-TNF-α to (A) PTE-, (B) AKE-, (C) SCE-, and (D) GBE-herbochips, which were fabricated with extracts from Pueraria thromsonii, Amumon
kravanh, Syzygium caryophyllaceum, and Garcinia bancans, respectively. These herbochips chosen to represent different binding signal strengths
from negative (−), weak (+), moderate (++), and strong (+++); as marked in Table 1.
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left ears.
Statistical analysis
The In vivo data are represented as Mean ± SE (10 animals
per group). The In vitro assay are comparison between
groups was made by One-way ANOVA, The differences
with p < 0.05 or p < 0.01 were considered significant or
highly significant, respectively.
Results
Herein, a refined Herbochip® screening platform was
constructed and reported. Treatment of the polystyrene
plastic slides with glutaraldehyde led to formation of free
aldehyde groups on the surface which subsequently
reacted with 1,4-butanediol diglycidyl ether. The resulted
terminally located epoxyl groups would then be able to
react with carboxyl-, hydroxyl-, amino-, and sulfhydryl-
groups to form covalent bonds. Thus most biological
molecules including nucleic acids, proteins, and small
molecules containing aforementioned functional groups
would be conjugated onto the surface-activated slides
(blank chips) when presented. The formatting of the
HPLC fractions onto the chip was presented in Figure 1.
After arraying, the unreacted epoxyl groups were blockedFigure 3 Binding signals of GWE-herbochip probed by β-TNF-α. (A) The im
β-TNF-α to the GWE-herbochip as described in Methods. (B) The fluorescen
presented (───) together with the original HPLC profile monitored at 2
biotin in Optifix I, 1 μg/mL SA-Cy5 in Optifix II (positive control) and Optifix
shown in Figure 1. Positive signals indicated binding activity of the fractionby ethanolamine in order to suppress background
staining. TNF-α binding activity of the HPLC fractionated
herbal extracts was unveiled by probing the herbochips
with biotinylated TNF-α, which was then visualized
by Cy5-conjugated streptavidin. Hybridization controls
were provided by the control spots on each chips
(Figure 1, C1-C6). C1-C4 samples containing different
concentrations of biotinamidocaproyl hydrazide were
used to indicate proper binding between biotin and
Cy5-conjugated streptavidin. While C5 and C6 samples
were used as internal negative and positive control,
respectively (Figure 1). It is also worth to note that Cave 1
on each chip was left blank (no target protein was added)
to serve as an additional control for the hybridization step
(Figures 2 and 3, left panels).
A total of 82 selected herbs were made into herbochips
and 46 herbs were found to possess TNF-α binding
activities (Table 1). As shown in Figure 2, the signals
of four herbochips, namely PTE (Pueraria thromsonii
extract)-, AKE (Amomum kravanh extract)-, SCE
(Syzygium caryophyllaceum extract)- and GBE (Garcinia
bancans extract)-herbochips, were chosen to represent
different binding signal strengths from negative binding
(−) to strong binding (+++). Likewise, TNF-α binding
activity of GWE-herbochip was shown in Figure 3.age was visualized by Cy5-labeled streptavidin after the binding of
ce intensity of the image was quantized by a scanner at 635 nm
54 nm (− − −−). The controls spots in (A) are 4, 10, 50, 250 ng/mL
I (negative control) were spotted onto the slide in the same format
s to TNF-α.
Figure 5 TNF-α inhibitory effects of the GWE. L929 cells were
treated with indicated concentrations of GWE in the presences of
1 ng/mg TNF-α. After 24 h of treatment, cell viability was determined
by MTT assays and TNF-α inhibitory effects of the test drugs were
expressed as % inhibition = (O.D.ActD+TNF-α+test drugs – O.D.ActD+TNF-α)/
(O.D.ActD – O.D.ActD+TNF-α). PC: Positive Control, 5 μg anti-TNF-α
antibody. The values show are mean ± S.E.M. (n =6). **P< 0.001
compared with the normal control group.
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indicated TNF-α binding (Figure 3A). Since the binding
activity was detected in a broad range of fractions and
only very little materials were eluted after fraction 68, the
GWE, with the typical HPLC profile shown in Figure 3B,
was used in all following experiments without further
fractionation.
The cytotoxic effects of GWE on L929 cells were assayed
in cultures exposed to GWE at indicated concentrations
for 24, 48, and 72 h. As shown in Figure 4, the test
drug GWE was found to be non-toxic at doses up to
128 μg/mL, at which slight enhancement of cell prolifera-
tion was found instead. In a slightly modified experimental
protocol, the TNF-α sensitive L929 cells were also used
for the assessment of the anti-TNF-α activity of GWE. It
was found that GWE exhibited anti-TNF-α activity in a
dose dependent manner, the degree of inhibition increased
from 8.75% to 93.32% when the drug doses increased from
16 to 128 μg/mL (Figure 5).
In the carrageenan-induced hind paw edema assay,
GWE inhibited swelling significantly 1 h post carrageenan
injection (Table 2). In the control rats, the average
swelling (n = 10) was 0.10 mL at 1 h, rose to 0.51 mL
at 2 h, peaked at 0.66 mL at 4 h, and subsided to
0.40 mL at 6 h post-carrageenan. In the GWE-treated
samples, the swelling rose from 0.07 mL to 0.14 mL
after 2 h of induction and subsided rapidly to the
baseline thereafter. The degrees of inhibition were
calculated to be 30%, 73%, 85%, and 80% at 1, 2, 4, and 6 h
post-carrageenan, respectively. This anti-inflammatory
effect of GWE, at a dose of 1.69 g/kg/d, which was
equivalent to 45 times of recommended dose for human
(9 g raw drug/d), was found to be stronger than the




















Figure 4 Cell viability at different concentrations of GWE. L929 cells
were treated with indicated concentrations of GWE for up to 72 h as
described in Methods. After treatments, cell viability was determined by
MTT assays. The values show are mean ± S.E.M. from three independent
experiments, no significance was found between groups.In fact, the anti-inflammatory effect of aspirin was
only moderate and disappeared at 6 h post-carrageenan.
These data indicated that when the animals were pre-fed
with GWE, the carrageenan-induced hind paw edema
could be significantly suppressed. The effect of GWE on
xylene-induced mouse ear edema was shown in Table 3.
Pretreatment of mice with GWE and aspirin resulted in a
statistically significant reduction of xylene-induced edema.
The degree of inhibition was calculated and it was
found that 1.69 g/kg/d of GWE reduced swelling by
33.3% (p < 0.01, compared to the control). The positive
control, aspirin (0.1 mg/kg/d), showed a 35.6% reduction
in swelling (p < 0.01) (Table 3).
Discussion
We have reported a microarray-based drug screening
platform referred to as the Herbochip® for target-based
discovery of natural compounds for functional char-
acterization and therapeutic uses. The application of this
platform was validated using TNF-α as the target for
screening and one of the results, namely the anti-
inflammatory fractions of the G. wilfordii extract (GWE),






Degree of swelling (mL)
1 h 2 h 4 h 6 h
Control − 0.10 ± 0.11 0.51 ± 0.07 0.66 ± 0.10 0.40 ± 0.06
GWE 1.69 g 0.07 ± 0.06 0.14** ± 0.08 0.10** ± 0.06 0.08** ± 0.06
Aspirin 0.10 mg 0.11 ± 0.12 0.39* ± 0.12 0.49* ± 0.14 0.39 ± 0.11
Data represent mean ± S.E.M. (n = 10). *p < 0.05; **p < 0.01.
Table 3 Effect of GWE on xylene-induced ear edema in mice
Test sample Dose (kg/d) Degree of swelling (mL) Inhibition (%)
Control − 8.7 ± 2.7 −
GWE 1.69 g 5.8 ± 2.2 33.3**
Aspirin 0.10 mg 5.6 ± 2.2 35.6**
Data represent mean ± S.E.M. (n = 10). *p < 0.05; **p < 0.01.
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most high-throughput-screening (HTS) formats, in which
large chemical libraries were screened against biological
targets via the use of automation, miniaturized assays and
large-scale data analysis [21,22], the Herbochip® platform
employed a reverse screening format, in which the potential
leads in herbal extract(s) were immobilized and selected
protein drug target was used as the probe for the screening
process [23]. In this Herbochip® platform the positive
controls were spots that contained different concentrations
of biotin (Figure 1, C1-C4, and C6). Additionally, one
of spots in each cave (Figure 5, C5, where no biotin
was present) and one of the caves (Cave 1) on each
chip (in which no biotinylated target protein was
added) served as negative controls. Together with the
blocking step, herbochips constructed this way validated
specific bindings between the immobilized ligands and the
protein targets.
During the course of this study, thousands of different
herbochips including the GWE-herbochip reported in
details here, were fabricated. The protein drug target
TNF-α was employed to screen 82 herbochips and the
hit rate was as high as 56% (46/82) when herbs reported
to have anti-inflammatory activity were counted. As
mentioned, the platform was initially used to screen for
herbal species that inhibit CYP450 3A4, an important
enzyme for the metabolism of a broad range of therapeutic
agents [18]. In addition to CYP450 3A4 and TNF-α,
preliminary positives were obtained for other protein
targets including vessel epithelial growth factor (VEGF),
glucose-regulated protein78 (GRP78), receptor activator
of NF-κB ligand (RANKL), etc., indicating that this novel
HTS platform could be applied to a wide range of known
drug targets. It is well known that the disease target of
most, if not all, of herbal medicines remain unknown, the
utilization of this target-based drug screening platform
on developments of herbal medicine is definitely worth
further explored.
TNF-α plays a central role in most inflammatory
responses and it is a validated target for drugs against a
number of chronic inflammatory disorders resulting from
immune dysregulations such as Crohn’s disease, ulcerative
colitis, ankylosing spondylitis, rheumatoid arthritis (RA),
[7,24,25]. Using TNF-α as a probe together with subse-
quent assays in cell and animal models, TNF-α inhibitory
activity and potential anti-RA activity in GWE were thusidentified and correlated. We have tried to fractionate the
GWE by solvent partition techniques and found that most
of the anti-RA activity was partitioned into an acetyl acet-
ate fraction. Unfortunately, the activity greatly diminished
in the fraction therefore only the crude GWE was used for
the studies reported. It is thus recommended that the total
ethanolic extract of GW is to be used for further anti-RA
drug development. Judging from the original chip profile
shown in Figure 2, the TNF-α binding/inhibitory activity
encompassed a large number of HPLC fractions, it is
conceivable that the active ingredients consisted of a large
derivatives may be a few natural compounds with similar
structures. The actual therapeutic effects shown in the
animal studies might result from the synergistically effects
of this mixture, thus explained the diminishment of TNF-α
inhibitory activity whenever the components were
separated by any form of fractionation. It is worth to
note that such phenomenon is not uncommon during the
development of herbal medicines by Western approaches.
In summary, these studies lead us to conclude that the
anti-rheumatoid activity of GWE can be attributed to its
inhibitory effect on the key inflammatory factor, TNF-α.
Our results contribute towards validation of the traditional
use of GWE in the treatment of RA and other inflamma-
tory joint disorders, which in turn may facilitate further
application traditional Chinese medicines in target-based
therapies.Conclusion
We have thus validated effectiveness of the Herbochip®
drug screening platform using TNF-α as a molecular target.
Subsequent experiments on GWE lead us to conclude that
the anti-RA activity of GWE can be attributed to inhibitory
effect of GWE on the key inflammatory factor, TNF-α. Our
results contribute towards validation of the traditional use
of GWE in the treatment of RA and other inflammatory
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